Michael Makris/LinkedIn
Feb 28, 2026, 16:16
Michael Makris: Lower Doses of Hemlibra May Still Be Effective
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn about his recent commentary, adding:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Authors: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF